Ensartinib is an anaplastic lymphoma kinase (ALK)-targeted oral capsule developed by Hutchison MediPharma. It was first approved for marketing in China in 2020, indicated for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC).
Ensartinib is a targeted therapy indicated for the treatment of a specific type of non-small cell lung cancer (ALK-positive NSCLC). It is available in capsule formulation, generally administered orally once daily on an empty stomach (at least 1 hour before meals or 2 hours after meals), with a recommended starting dose of 225 mg. Dose adjustment should be performed during treatment based on the severity of individual adverse reactions.
Dosage, Administration and Dose Adjustment
1.Method
The capsule should be swallowed whole once daily, and administration with food should be avoided (take at least 1 hour before meals or 2 hours after meals).
2.Starting Dose
The standard starting dose is 225 mg once daily.
3.Dose Adjustment Principles
(1) Dose reduction is required when severe (Grade 3 or 4) adverse reactions occur. The dose should be reduced to 200 mg once daily for the first time, and further reduced to 150 mg once daily for the second time. If Grade ≥3 adverse reactions still occur at the 150 mg dose, permanent discontinuation of the drug is recommended.
(2) For nausea, vomiting or diarrhea, standardized antiemetic/antidiarrheal treatment should be given first. If symptoms remain severe or intolerable, treatment should be suspended (for a maximum of 4 weeks) and supportive care should be administered. After symptoms alleviate to mild (Grade ≤1): treatment can be resumed at 200 mg for the first occurrence; for recurrent occurrence, treatment should be resumed at 150 mg.
Pharmacokinetic Characteristics
1.Metabolism and Excretion
Ensartinib undergoes extensive metabolism in the body, mainly through amide bond hydrolysis, oxidation and other pathways. The main metabolites have comparable activity to the parent drug.
2.Elimination Route
After oral administration, the drug is mainly eliminated via feces (approximately 91%, of which 38% is the parent drug), with a small portion excreted in urine (approximately 10%, of which 4% is the parent drug).
3.Half-life and Clearance Rate
The average half-life after a single dose is approximately 28.8 hours. The clearance rate at steady state (32.4 L/h) is lower than that after a single dose (41.8 L/h), indicating a certain degree of drug accumulation in the body.
Key Points for Adverse Reaction Management
1.Gastrointestinal Reactions (nausea, vomiting, diarrhea)
Standardized symptomatic treatment (e.g., administration of antiemetic/antidiarrheal drugs) should be prioritized. If symptoms persist and are severe, the drug should be suspended and the dose adjusted in accordance with the above principles.
2.Monitoring and Communication
During treatment, regular monitoring of liver function, electrocardiogram (ECG) and other indicators is required. Any persistent or worsening adverse effects should be promptly reported to the physician. Patients are advised not to discontinue or adjust the dose of the drug without medical supervision.
Contraindications and Precautions
1.Contraindicated Populations
Patients with hypersensitivity to any component of ensartinib; patients without confirmed ALK-positive status.
2.Special Populations
(1) The drug is contraindicated in pregnant women (as it may cause fetal harm), and breastfeeding should be discontinued during treatment.
(2) Caution should be exercised in patients with hepatic or renal impairment, and the drug should be used only after evaluation by a physician.
Drug Interactions
1.CYP3A4 Inhibitors/Inducers
These drugs may affect the plasma concentration of ensartinib. Patients should inform their physician of all medications they are taking (e.g., antifungal drugs, antiepileptic drugs).
2.Gastric Acid Modifiers
Concurrent use with proton pump inhibitors (e.g., omeprazole) should be avoided. If necessary, the administration time should be adjusted under the guidance of a physician.
Storage and Shelf Life
1.Storage Conditions
Store in a light-protected place at 20-25℃, and protect from moisture.
2.Shelf Life
Subject to the label on the package. Do not use the drug after the expiration date.
Important Notice: Ensartinib is a prescription drug and should be used only after evaluation by a qualified physician. During treatment, regular monitoring of liver function, heart rate and pulmonary conditions is required. Patients should contact their physician immediately if any discomfort occurs.
